Pacific Biosciences of California (PACB) 8-K Results of Operations and Financial Condition

Exhibit 99.3

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three-Month Periods Ended March 31,
(in thousands)	2013			2012
Cash flows from operating activities
Net loss	$	(21,104	)	$	(27,580	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		1,493			1,629
Stock-based compensation		2,746			2,187
Other items		121			53
Changes in assets and liabilities
Accounts receivable		813			3,052
Inventory		(607	)		3,094
Prepaid expenses and other assets		431			245
Accounts payable		22			(492	)
Accrued expenses and other current liabilities		(779	)		1,220
Deferred revenue		(423	)		(489	)
Lease incentives and other long-term liabilities		(288	)		(257	)
Net cash used in operating activities		(17,575	)		(17,338	)
Cash flows from investing activities
Purchase of property and equipment		(297	)		(274	)
Purchase of investments		(42,466	)		(20,137	)
Sales of investments		—			3,500
Maturities of investments		37,180			29,889
Net cash provided by (used in) investing activities		(5,583	)		12,978
Cash flows from financing activities
Proceeds from issuance of common stock, net of underwriting fees		10,136			1,755
Proceeds from issuance of debt facility, net of underwriting fees		20,000			—
Debt facility issuance costs		(234	)		—
Common stock issuance costs		(246	)		—
Net cash provided by financing activities		29,656			1,755
Net increase (decrease) in cash and cash equivalents		6,498			(2,605	)
Cash and cash equivalents at beginning of period		46,540			58,865
Cash and cash equivalents at end of period	$	53,038		$	56,260
Supplemental disclosure of non-cash investing and financing activities
Inventory transferred to (from) property and equipment	$	(398	)	$	602